Pharmokinetics

Scientist working in the lab
#3D cell culture #3D modelling #ADME / Tox #Drug toxicity #Pharmokinetics #Webinar

Last chance: Optimise ADME/Tox testing with advanced cell models

Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More

Webinar date:
Supported by Lonza
#News

Medical research
#3D cell culture #3D modelling #ADME / Tox #Drug toxicity #Pharmokinetics #Webinar

Building advanced cell models for toxicity testing: Register today

Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More

Webinar date:
Supported by Lonza
#News

Biosafety testing
#3D cell culture #3D modelling #ADME / Tox #Drug toxicity #Pharmokinetics #Webinar

Free event: Next generation predictive in vitro ADMET solutions

Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More

Webinar date:
Supported by Lonza
#News

Researcher in a medical lab
#3D cell culture #3D modelling #ADME / Tox #Drug toxicity #Pharmokinetics #Webinar

Webinar: Create advanced predictive models for tox testing

Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More

Webinar date:
Supported by Lonza
#News

Scientist working in the lab
#3D cell culture #3D modelling #ADME / Tox #Drug toxicity #Pharmokinetics #Webinar

Webinar: Building advanced cell models for toxicity testing

Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More

Webinar date:
Supported by Lonza
#News

Scientist working in the lab
#3D cell culture #3D modelling #ADME / Tox #Drug toxicity #Pharmokinetics

Building advanced cell models for toxicity testing

Life sciences researchers need a host of tools to develop and test critical disease-treating drugs and therapies, from basic research to final product release. Primary cells, media, and reagents are all important for supporting preclinical and clinical pharmaceutical workflows for drug discovery and absorption, distribution, metabolism, excretion, and toxicity (ADMET)… Read More

Webinar date:
Supported by Lonza
#Webinars

Antibodies
#Guide #Human disease models #Mouse models #Pharmokinetics #Therapeutic Antibodies

Guide: Assessing preclinical PK in therapeutic antibodies

A new Guide is now available from The Jackson Laboratory (JAX) entitled ‘HuPK: A Humanised Platform for therapeutic antibody PK evaluation’. Download the Guide to learn more about:   How JAX’s HuPK™ Humanised FcRn Platform offers a validated and… Read More

#News

#Drug development #Drug discovery #Guide #Human disease models #Mouse models #Pharmokinetics

HuPK: A Humanised Platform for therapeutic antibody PK evaluation

Download the guide to learn more about:   How JAX’s HuPK™ Humanised FcRn Platform offers a validated and cost-effective solution for assessing the in vivo  preclinical pharmacokinetics and stability of Fc-based biologics and therapeutics carried by albumin.    JAX’s… Read More

#Intelligence #Resources

eBook
#Biosensors #Drug discovery #eBook #Interaction analysis #Molecular research #Pharmokinetics

Binding kinetics in hours instead of days – download the eBook

A new eBook is now available from Malvern Panalytical: ‘Faster, more accurate and deeper insight: How to make the switch to label-free interaction analysis.’ Label-free interaction analysis takes discovery to a new level. It removes inaccuracies and inefficiencies, but it also uncovers a new layer of insight… Read More

#News

#Biosensors #Drug discovery #Interaction analysis #Molecular research #Pharmokinetics

Binding kinetics in hours instead of days with label-free interaction analysis

Label-free interaction analysis takes discovery to a new level. It removes inaccuracies and inefficiencies, but it also uncovers a new layer of insight into the kinetic activity and binding specificity of a greater range of analytes. GCI technology brings you closer to your analytes, allowing you to see interactions in… Read More

#Resources

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Organic chemistry #Pharmokinetics #Precision medicine #RNA #Screening #System biology #Systems biology #Therapeutics #Toxicology

The COVID-19 antiviral race: we’re all in this together

The COVID-19 antiviral race: we’re all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Clinical specialities #Drug development #Enabling technologies #Flow Cytometry #Genetics / genomes #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead optimisation #Microfluidics #PCR #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Toxicology

Creating vaccines drop by drop

By Richard Gray The recent outbreak of COVID-19 has highlighted the need for fast and efficient development and production of vaccines for a whole gamut of pathogens, old and new. Microfluidics technologies can be used to accelerate the vaccine development process in a number of ways,… Read More

#Covid-19 #Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Pharmokinetics #Preclinical #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The CELL CULTURE innovations increasing drug discovery success

The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development… Read More

#Exclusive Content

#Business #Drug development #Drug discovery #Pharmacology #Pharmokinetics #Screening

The Kinetics of Drug-Receptor Binding: Why it is important and how we can measure it?

The Kinetics of Drug-Receptor Binding: Why it is important and how we can measure it? Sponsored by BMGLabtech & CISBio Optimizing the receptor binding kinetics of new drugs can have significant benefits, ranging from improved duration of action to enhanced efficacy through the… Read More

Webinar date:
Sponsored by BMG Labtech & CISBio
#Webinars

#Academic #Analysis #Assay development optimisation & technology #Business #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Immunology #Lead discovery #Microfluidics #Pharmokinetics #Screening #Therapeutics

Carterra closes financing round for LSA platform

Carterra closes financing round for continued growth of the LSA platform for next generation antibody dscovery. Carterra has closed a $6M round of financing led by Ballast Point Ventures with participation from current investor, Telegraph Hill Partners. The additional funding will support the continued adoption… Read More

#News

#Academic #Biomarkers #Drug discovery #Drug targets #Immunology #Immunology / Virology & Vaccines #Pathology #Pharmokinetics #Stem cells

Creoptix collaboration to characterise anti-SARS-CoV-2 antibodies

15 May, 2020 The Swiss next-generation bioanalytical instruments specialist announced a collaboration with Adriano Aguzzi, Professor for Neuropathology, University of Zurich, to characterise immunological responses to SARS-CoV-2 such as IgA, IgM and IgG antibodies, which signal whether an individual has been exposed to the coronavirus. The collaboration aims… Read More

#News